In an article in the same issue of the MJA, Dr Sanjaya Senanayake an infectious diseases specialist at the Canberra Hospital Department of Microbiology, there has been a consistent increase in mumps notifications in Australia in recent years, with nearly 600 reports in 2007. – Three quarters of them were for people aged 20 or older.
The Phase III clinical trial of prGCD is a multicenter, randomized, double – blind, parallel group, dose-ranging study to evaluate the safety and efficacy of diagnoses prGCD in previously untreated patients with Gaucher disease. In the study patients were randomized to to one of two dosing arms and received IV infusions elected every two weeks for nine months. The primary endpoint of the study is the reduction in spleen volume from baseline, as measured by MRI.Image courtesy of to can use the entire Kaiser view Daily Health Policy Report, J.earch the archives , or sign up for email infeed at Kaiser Daily Health policy coverage from press for royal network. A free service of of The Henry J. Published. Kaiser Family Foundation. 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.